<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04988594</url>
  </required_header>
  <id_info>
    <org_study_id>FMSParaguay</org_study_id>
    <nct_id>NCT04988594</nct_id>
  </id_info>
  <brief_title>Effects of Yogurt With Probiotics in Adults With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A 12-weeks Double Blind Trial of Effects of Yogurt With Probiotics in Adults With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faculty of Medical Sciences, Clinical Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faculty of Medical Sciences, Clinical Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to analyze the effects of the consumption of yogurt with&#xD;
      concentrated and lyophilized probiotic cultures on the parameters associated with glucose&#xD;
      homeostasis, inflammation and oxidative stress in patients with Type 2 Diabetes Mellitus&#xD;
      (T2DM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and the potential risks, all patients who gave their&#xD;
      written informed consent underwent a screening period of 1 week to determine their&#xD;
      eligibility to participate in the study. At week 0, patients who met the eligibility&#xD;
      requirements were randomized in a double-blind manner (participant and investigator) to the&#xD;
      American Diabetes Association (ADA) diet + yogurt with premium probiotics (300 g/d) or ADA&#xD;
      diet + conventional yogurt (300 g/d) or ADA diet without fermented dairy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Actual">April 30, 2021</completion_date>
  <primary_completion_date type="Actual">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in parameters associated with glucose homeostasis</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>At time 0 and after 12 weeks of intervention and follow-up, it was determined in mg/dL following the protocols established for: HDL-c (high-density lipoprotein cholesterol), LDL-c (low-density lipoprotein cholesterol), triglycerides and glucose. Likewise, glycosylated hemoglobin (HbA1c in percentage) was determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory parameters</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>At time 0 and after 12 weeks of intervention and follow-up, the high sensitivity C-reactive protein (hs-CRP) was determined in plasma in mg/dL. Likewise, interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-a) in ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in oxidative stress parameters</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>Superoxide dismutase, glutathione peroxidase and catalase (SOD, GPx, CAT, respectively) will be measured in U/mg by spectrophotometry at time 0 and after 12 weeks of intervention and follow-up.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Premium probiotic yogurt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 300 g/d of yogurt with concentrated and freeze-dried probiotic cultures for 12 weeks. Also, the nutritional recommendations of the American Diabetes Association (ADA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional yogurt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 300 g/d of conventional yogurt for 12 weeks. Also, the nutritional recommendations of the American Diabetes Association (ADA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no fermented dairy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants followed the American Diabetes Association (ADA) recommendations without including fermented dairy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus acidophilus 207, Bifidobacterium lactis B420/205</intervention_name>
    <description>Cultures containing 3.7 × 10 ^ 9 CFU/mg</description>
    <arm_group_label>Premium probiotic yogurt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus bulgaricus and Streptococcus thermophillus</intervention_name>
    <description>Cultures containing 3.7 × 10 ^ 6 CFU/mg</description>
    <arm_group_label>Conventional yogurt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>No culture</intervention_name>
    <description>No probiotic cultures</description>
    <arm_group_label>no fermented dairy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with T2DM diagnosed at least one year ago.&#xD;
&#xD;
          -  That they are outpatients.&#xD;
&#xD;
          -  Between 25 and 65 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoking patients.&#xD;
&#xD;
          -  Lactose intolerance.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Presence of kidney, liver, immunodeficiency, inflammatory bowel disease or thyroid&#xD;
             disorder.&#xD;
&#xD;
          -  Use of insulin, estrogen, progesterone or diuretic injections.&#xD;
&#xD;
          -  Consumption of probiotic supplements two months before the start of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Perez Martinez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Maimonides de Investigacion Biomedica de Cordoba, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Ruiz Diaz Narvaez, DN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medical Science, Paraguay</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Maimonides de Investigacion Biomedica de Cordoba</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Faculty of Medical Sciences, Clinical Hospital</investigator_affiliation>
    <investigator_full_name>Maria Eugenia Ruiz Diaz Narvaez</investigator_full_name>
    <investigator_title>Clinical Nutritionist</investigator_title>
  </responsible_party>
  <keyword>probiotics</keyword>
  <keyword>glucose homeostasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

